STRO Live signals | Maximize Profits with Getagraph.com

BUY 101559 min ago

@ $4.45

Issued: 14 Feb 2024 @ 13:11

Return: -22.04%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -4.28 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	541 056
Average Volume	1.00M
Market Cap	266.91M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.880 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.950
ATR14	$0.00800 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Srinivasan Venkatesh	Sell	21 250	Restricted Stock Unit (RSU)
2024-04-11	Srinivasan Venkatesh	Buy	21 250	Common Stock
2024-04-11	Srinivasan Venkatesh	Sell	7 582	Common Stock
2024-03-05	Newell William J	Buy	167 000	Restricted Stock Units (RSUs)
2024-03-05	Fitzpatrick Linda A	Buy	37 100	Restricted Stock Units (RSUs)

INSIDER POWER
67.79
Last 99 transactions
Buy: 2 171 384 \| Sell: 404 320

Volume Correlation

Long: -0.13 (neutral)

Short: -0.81 (strong negative)

Signal:(54.908) Neutral

Sutro Biopharma Inc Correlation

10 Most Positive Correlations
TNGX	0.88
CARA	0.864
EYE	0.821
SLM	0.809
ACHC	0.801
LSXMK	0.801

10 Most Negative Correlations
ALR	-0.839
INZY	-0.833
BTBD	-0.83
INOD	-0.828
GETVV	-0.826
HYPR	-0.824
FTIV	-0.812
OCUL	-0.803
SELF	-0.802

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sutro Biopharma Inc Correlation - Currency/Commodity

-0.62
( weak negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.88
( strong negative )

0.70
( moderate )

Sutro Biopharma Inc Financials

Annual	2023
Revenue:	$153.73M
Gross Profit:	$146.92M (95.57 %)
EPS:	$-1.780

Q4	2023
Revenue:	$113.72M
Gross Profit:	$111.99M (98.48 %)
EPS:	$0.510

Q3	2023
Revenue:	$16.92M
Gross Profit:	$15.19M (89.72 %)
EPS:	$-0.810

Q2	2023
Revenue:	$10.41M
Gross Profit:	$8.02M (77.00 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.